Prohost Letter #405
Synthetic Biology (3)

We have already decided upon becoming shareholders the day synthetic biology firm called Synthetic Genomics turns public. We reiterate that firms specialized in synthetic biology are numerous private and publicly traded. Some are promising, others are walking in place and a few have plummeted. With the general underperformance of synthetic biology stocks, many shareholders abandoned ship. Investors felt that their dreams about giant accomplishments at with synthetic biology publicly-­traded firms have evaporated.

We believe, that the time has come for some of the synthetic biology firms to . . .